Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML
    Research Letter

    Mason, E. F.; Pozdnyakova, O.; Roshal, M.; Fathi, A. T.; Stein, E. M.; Ferrell, P. B.; Shaver, A. C.; Frattini, M.; Wang, H.; Hua, L.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML
    Journal Article

    Chen, B. R.; Deshpande, A.; Barbosa, K.; Kleppe, M.; Lei, X.; Yeddula, N.; Sánchez Vela, P.; Campos, A. R.; Wechsler-Reya, R. J.; Bagchi, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • ADCLEC.syn1 is a novel combinatorial CAR platform for enhanced therapeutic index in AML
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Nataraj, S.; Park, J.; Wang, X.; Rivière, I.; Sadelain, M.
    Molecular Therapy (2021)

    Fulltext@MSK | Save
  • Mechanisms of adoptive T cell micropharmacies
    Meeting Abstract

    Bourne, C. M.; Dacek, M. M.; Bah, M. A.; Romero-Pichardo, J.; Gardner, T. J.; Lee, P.; Tan, D.; Scheinberg, D. A.
    Molecular Therapy (2021)

    Fulltext@MSK | Save
  • Predictors for neurotoxicity on day of infusion of chimeric antigen receptor (CAR) T cells using discovery proteomics platform
    Meeting Abstract

    Lakkaraja, M.; Hosszu, K.; McAvoy, D.; Mauguen, A.; Purdon, T. J.; Auchincloss, T.; Klein, E.; Khakoo, Y.; Santomasso, B.; Senechal, B.; more...
    Cytotherapy (2021)

    Fulltext@MSK | Save
  • Radiation therapy enhances the presentation of phosphopeptides by MHC-I on cancer cells
    Meeting Abstract

    Van Nest, S. J.; Yaron, T. M.; Klatt, M. G.; Dephoure, N. E.; Getz, G.; Santambrogio, L.; Elemento, O.; Scheinberg, D.; Demaria, S.; Cantley, L. C.
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Eyre, T.; Shah, N. N.; Alencar, A.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as "add-on" to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: Update of MANIFEST phase 2 study
    Meeting Abstract

    Somervaille, T.; Verstovsek, S.; Mascarenhas, J.; Kremyanskaya, M.; Hoffman, R.; Rampal, R.; Gupta, V.; Talpaz, M.; Granacher, N.; Leber, B.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: Update of manifest phase 2 study
    Meeting Abstract

    Mead, A.; Mascarenhas, J.; Talpaz, M.; Patriarca, A.; Devos, T.; Palandri, F.; Passamonti, F.; Rampal, R.; Kremyanskaya, M.; Scandura, J.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory/intolerant to JAK inhibitor: Update from phase 2 MANIFEST study
    Meeting Abstract

    Drummond, M.; Talpaz, M.; Rampal, R.; Verstovsek, S.; Kiladjian, J. J.; Vannucchi, A.; Kremyanskaya, M.; Schiller, G.; Patriarca, A.; Van Gorkom, G.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save